Document:

oskarepagreement

                  DNAPRINT/OSKAREP PRIVATE PLACEMENT AGREEMENT

This Private Placement Agreement (this "Agreement") is made and entered into as
of January ____, 2002 (the "Effective Date") by and between DNAprint genomics, a
Utah corporation, (hereinafter "DNAPRINT") and John Oskarep (hereinafter
"PARTY").

Recitals

DNAPRINT is the inventor of certain intellectual property (software algorithms
for developing genetic tests) and desires to file patent covering these
properties.

PARTY is a lawyer who drafts, prosecutes and maintains such patent applications.

NOW, THEREFORE, in consideration of these premises, as well as the obligations
herein made and undertaken, the parties hereto do hereby agree as follows:

1. COMPENSATION
Provision. PARTY is willing to accept DNAPRINT stock as compensation for his services.
        1.1     Designation. For the Correspondence/Linear+Quadratic method for
                modeling genetic features, and the Classification Tree Methods
                patents (PATENTS), PARTY will designate invoices to be paid under
                the terms of this agreement. At the discretion of PARTY, PARTY
                may from time to time designate other invoices to be paid under
                the terms of this agreement.
        1.2     Payment. Subject to the terms and conditions of this agreement,
                and upon receipt of an invoice designated by PARTY as subject to
                the terms of this agreement, DNAPRINT agrees to pay such invoice
                by issuing DNAPRINT stock.
        1.3     Terms. The number of shares DNAPRINT will issue to pay the
                invoice will be determined by using an average share price for
                the 14 business day preceding (look-back) share price. The shares
                will be restricted 1-year from the date of issue.
        1.4     Transfer. DNAPRINT will physically transfer shares to PARTY
                through regular mail service.

2. CONTINUATION, TERM and TERMINATION.
        2.1     Services. The agreement specifically covers PATENTS but will
                extend indefinitely until terminated. During the term of this
                agreement, PARTY has the right to designate those invoices,
                whether for the PATENTS or subsequent patents, for which he is
                willing to accept stock as payment. Subsequent to the filing and
                compensation for the PATENTS, PARTY or DNAPRINT can terminate the
                agreement at any time. If DNAPRINT terminates the agreement, all
                future invoices will be payable in cash consistent with standard
                payment terms of PARTY.

3. RESTRICTIONS
        3.1     Amendments. DNAPRINT and GENOMED may sign subsequent amendments
                to this Agreement.

4. ASSURANCES

        4.1     Prospectus. PARTY confirms that he has read DNAPRINT's private
                placement memorandum, and the company's most recent annual report
                available from DNAPRINT or through the internet
                (WWW.FREEEDGAR.COM).

7. Mediation and Arbitration
        7.1     Mediation and arbitration approach. The parties agree to select a
                mutually agreeable, neutral third party to help them mediate any
                dispute that arises under the terms of this Agreement. Costs and
                fees associated with the mediation will be shared equally by the
                parties.

                                       1

        7.2     Arbitration. If the mediation is unsuccessful, the parties agree
                that the dispute will be decided by binding arbitration under the
                rules of the American Arbitration Association. The decision of
                the arbitrators will be final and binding on the parties and may
                be entered and enforced in any court of competent jurisdiction by
                either party. The prevailing party in the arbitration proceedings
                will be awarded reasonable attorney fees, expert witness costs
                and expenses, and all other reasonable costs and expenses
                incurred in connection with the proceedings, unless the
                arbitrators for good cause determine otherwise.

8. General

        8.1     Notices. Any notice required or permitted hereunder must be in
                writing, and will be effective on the date of delivery when
                delivered personally, the next business day after dispatch when
                sent by Federal Express or other recognized overnight courier
                service, or the fifth business day after dispatch when sent by
                certified mail, postage prepaid, return receipt requested.
                Notices should be addressed to the other party at the address
                shown below or at such other address as a party may designate by
                ten days' advance written notice to the other party:

         DNAPRINT GENOMICS, INC.                     GENOMED INC.
         900 Cocoanut, Ave.                          4560 Clayton Ave.
         Sarasota, FL 34236                          St. Louis, MO 63110

        8.2     Entire Agreement; Modifications. This Agreement constitutes the
                entire agreement of the parties with respect to the subject
                matter hereof and supersedes all prior representations,
                proposals, discussions, and communications, whether oral or in
                writing. This Agreement may be modified or amended only by a
                writing executed by a duly authorized representative of each
                party.
        8.3     Force Majeure. Neither party will be liable to the other for any
                failure or delay caused by events beyond such party's control,
                including, without limitation, sabotage, terrorism, riots,
                insurrections, fires, flood, storm, explosions, war or
                earthquakes. However, if such events have a material impact on
                the satisfaction of this Agreement, and shall continue for thirty
                (30) days or more, the other party shall have the option of
                terminating this Agreement by giving written notice of
                termination.
        8.4     Change in Law; Change in Circumstances. No party shall make or
                receive any payment or take any action under this Agreement if
                any judicial decision, legislative action, or regulatory or other
                administrative interpretation, whether federal or state, would
                render illegal the conduct of either party under this Agreement.
                If performance by either party of any term of this Agreement
                should be deemed illegal by any party or third party who is
                essential to performance of this Agreement for any such reason,
                either party shall have the right to require that the other party
                renegotiate the terms of this Agreement.
        8.5     Assignment. This Agreement will be binding upon and inure to the
                benefit of the parties hereto, their successors and permitted
                assigns. Either party may assign this Agreement in its entirety
                to a successor corporation upon notice to the other party in the
                event of a merger or an acquisition of all or substantially all
                of the assets of the assigning party.
        8.6     Governing Law. All questions concerning the validity, operation,
                interpretation, and construction of this Agreement will be
                governed by and determined in accordance with the laws of the
                State of California, without regard to its conflict of laws
                provisions. Application of the United Nations Convention on
                Contracts for the International Sale of Goods is specifically
                excluded.
        8.7     Severability. If a court of competent jurisdiction determines
                that any provision of this Agreement is invalid, illegal, or
                otherwise unenforceable, such provision shall be replaced with a
                valid, enforceable provision as nearly as possible in accordance
                with the stated intention of the paties, while the remainder of
                this Agreement shall remain in full force and effect. To the
                extent any provision cannot be enforced in accordance with the
                stated intentions of the parties, such provision shall be deemed
                not to be a part of this Agreement.
        8.8     Counterparts. This agreement may be executed in any number of
                counterparts, all of which together will constitute one and the
                same instrument.

                                       2

IN WITNESS THEREOF, the parties have caused this Agreement to be executed by
their respective duly authorized representatives as set forth below:

DNAPRINT GENOMICS                           GENOMED

By:/s/Tony Frudakis                         By:/s/Jerry White
Tony Frudakis, Ph.D.                        Jerry White
CEO                                         CEOgenbiomicsconsultingagmt

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

                              CONSULTANT AGREEMENT

THIS CONSULTANT AGREEMENT (the Agreement), is entered into effective as of
Friday, 17 May 2002 (the Effective Date) by and between DNAPrint Genomics, Inc.,
doing business at: DNAPrint Genomics, Inc. 900 Coconut Ave., Sarasota, FL. 34236
(herein referred to as "Client") and GenBiomics, LLC with offices at 505
Paradise Rd., #281, Swampscott, MA 01907 (herein referred to as "Consultant").

A.  Client is in the  business  of  genomics  discovery  and  genomics  products
development  and in the conduct of said  business  desires to have the following
services, as a consultant, to be performed by consultant.

B.  Consultant  agrees to perform the  services  for Client  under the terms and
conditions set forth in this agreement.  In consideration of the mutual promises
set forth herein it is agreed by and between Client and consultant as follows:

1. Term

This Agreement shall begin on the effective Date and expire on December 31,
2005, unless sooner terminated in accordance with the terms of this agreement.
This agreement may be extended for additional periods by mutual agreement of
Consultant and Client. Any agreement to extend this Agreement must be confirmed
in writing signed by all parties to this Agreement.

2. Area of Consultation

2.1 Consultant will consult with and advise Client on the development of its
scientific and business plans aimed at identifying and optimising financing
strategies, structures and investors, focusing on equity capital for both
private placement and public offering of additional stock issues relating to
Client's business development program. In addition this agreement shall cover
issues relating to regulatory aspects in the equity management process as well
as overall corporate operational controls, measures and implementation of said
agreed upon strategies.

2.2 All communications and reports from Consultant shall be directed to Dr. Tony
Frudakis, Chief Executive Officer, President and Chief Scientific Officer of
DNAPrint Genomics, Inc.

2.3 Each particular service rendered by Consultant and the approximate time
requirement has to be defined and agreed in a separate letter, heretofore
referred to as an "Addendum to the Contract". Unless such service and estimated
time requirement is agreed upon between the parties' consultant is not entitled
to claim for payment or compensation. If the services rendered by consultant
will exceed the estimated time requirement by more than 10% consultant will

                                       1

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

inform Client immediately. Rendering further services by the consultant (i.e.
services exceeding the estimated time requirement by more than 10%) are subject
to the prior written approval of Client. Without such approval consultant is not
entitled to claim for payment or compensation for all services rendered which
exceed the estimated time requirement by more than 10%.

3. TIME DEVOTED TO WORK

In the performance, the aforesaid services and the hours consultant is to work
on any given day will be entirely within consultant's control and Client will
rely upon consultant to put in effort as is reasonably necessary to fulfil the
spirit and purpose of this contract. Consultant will provide monthly reports
with tracking of hours and subject of the work.

4. PLACE OF WORK

Consultant's services will be rendered largely at of 20 Blodgett Ave.
Swampscott, MA 01907, as well as, 5105 Rue Vendome, Lutz, FL 33549 and 1135
Catherine Lane, Corvallis MT 59828; but consultant will, on request, come to
Client's address of 900 Coconut Ave., Sarasota, FL. 34236 or such other places
designated by Client to meet with representatives of Client.

5. PAYMENT

5.1 Except as otherwise set forth herein, Client shall pay Consultant, and
Consultant shall accept for Consultant's services under this Agreement a
compensation of a consultancy rate that is determined on a project by project
basis and is clearly defined and agreed to by both parties and as found as
"Addendum to the Contract". The payment will be based on the prorate monthly
basis of the "Addendum to the Contract" and as defined by the mutually signed
and agreed to "Addendum to the Contract". Payment, as defined by the "Addendum
to the Contract" and may vary from time to time and may be paid in the form of
market securities, restricted securities, options, cash or other forms of
compensation, shall be made upon receipt of the invoice within 30 days or as in
the case of agreed to expenses, paid within 10 days of receipt of invoice in
accordance with the terms and conditions of this contract and as so modified and
agreed to by both parties in the attached "Addendum to the Contract".

5.2 Consultant acknowledges that Client may report payments to United States and
State tax authorities

5.3 Upon receipt by Client of original receipts of expenditures by Consultant,
Client shall reimburse Consultant for reasonable expenses incurred by
Consultant, at the request and with the prior written approval of Client, in
rendering services hereunder and that upon receipt shall pay Consultant within
10 days of said receipt.

6. STATUS OF CONSULTANT

                                       2

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

The consultant is engaged as an independent contractor and shall be treated as
such for all purposes, including but not limited to, Federal and State taxation,
withholding, unemployment insurance, and worker's compensation. Consultant will
not be considered an employee of Client for any purpose.

7. TRADE SECRETS AND CONFIDENTIAL INFORMATION

7.1 DNAPrint Genomics, Inc. CONFIDENTIAL INFORMATION

Any trade secrets or any other information of value relating to the business
and/or field of interest of Client or any of its Affiliates including, but not
limited to, information relating to inventions, disclosures, process, systems,
methods, formulae, devices, patents, patent applications, trademarks,
intellectual properties, instruments, materials, products, research or
development activities and plans, clinical, pre-clinical, or other data,
specifications, computer programs, costs of production, prices or other
financial data, volume of sales, promotional methods, marketing plans, strategic
plans, lists of names or classes of customers, or lists of suppliers, that
Consultant obtains through its consultant capacity with Client during the term
of this Agreement, or may have acquired through previous dealings with Client or
any of its Affiliates, shall be regarded as held by Consultant in a fiduciary
capacity solely for the benefit of Client, its successors or assigns, and shall
not at any time, either during the term of this Agreement, or thereafter, be
disclosed, divulged, furnished or made accessible by Consultant to anyone, or be
otherwise used by Consultant, expect in the regular course of Consultant's
providing services for Client under this Agreement. Information shall for
purposes of this Agreement be considered to be secret if not known by the public
generally, even though such information may have been disclosed to one or more
third parties pursuant to agreements entered into by Client or its Affiliates.

7.2 THIRD PARTY CONFIDENTIAL INFORMATION

Consultant shall not divulge any information to Client pursuant to this
agreement that is the proprietary property of a third party.

8. ASSIGNMENT OF INVENTIONS AND OTHER INTELLECTUAL PROPERTIES

8.1 ASSIGNMENT

Consultant agrees to and does hereby sell, assign, transfer and set over to
Client, its successors or assigns, as the case may be, of all Consultant's
right, title and interest in and to any texts, writings or video or audio
recordings produced hereunder (whether copyrighted or not) as well as any
copyrights, software, inventions, improvements, processes, patents or
applications for patents that Consultant develops or conceives individually or
in conjunction with others, as a result of or in connection with the services
rendered by Consultant for Client in the Area of Consultation, to be held and

                                       3

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

enjoyed by Client, its successors or assigns, as case may be, to the full extent
of the term for which any Letters Patent may be granted and as fully as the same
would have been held by Consultant had this Agreement, sale or assignment not
been made.

8.2 DOCUMENTS NECESSARY

Consultant shall make, execute and deliver any and all instruments and documents
and perform any and all acts necessary to obtain, maintain and enforce patents,
trademarks and copyrights for such inventions, improvements, processes and
writings, as Client may desire in any and all countries. All costs, expenses of
application and prosecution of such patents, trademarks and copyrights shall be
paid by Client.

8.3 ORIGINALS

Upon Client's request, Consultant shall deliver all original text (including the
floppy disks containing such text), tapes, artwork and other items created or
obtained for Employer under this Agreement.

8.4 EXCLUSIONS

For the avoidance of doubt the parties agree that the Consultant's intellectual
property, ideas, concepts, programs, software, chemical libraries, compounds,
any trade secrets or any other information of value relating to the business
and/or field of interest of Consultant or any of its Affiliates including, but
not limited to, information relating to inventions, disclosures, process,
systems, methods, formulae, devices, patents, patent applications, trademarks,
intellectual properties, instruments, materials, products, research or
development activities and plans, clinical, pre-clinical, or other data,
specifications, computer programs, costs of production, prices or other
financial data, volume of sales, promotional methods, marketing plans, strategic
plans, lists of names or classes of customers, or lists of suppliers
(hereinafter effectively referred to as "Items"), shall remain in Consultant's
sole and exclusive ownership, unless (i) otherwise agreed in this Agreement or
in a separate contract between the parties, and/or (ii) unless Client receives,
obtains or is informed about such Items from/by Consultant as a result of or in
connection with the services rendered by Consultant for Client in the Area of
Consultation under this Agreement, or such Items are conceived, disclosed,
divulged, furnished or made accessible by Consultant to Client as a result of or
in connection with the services rendered by Consultant for Client in the Area of
consultation under this Agreement.

9. NOTICE

Any notice required or permitted to be given hereunder shall be deemed
sufficient if sent by facsimile letter or overnight courier, or delivered by
hand to Client or Consultant at the respective addresses first given above or at
such other address as either party hereto may designate. If sent by facsimile

                                       4

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

letter notice shall be deemed given when the transmission is completed if the
sender has a confirmed transmission report. If a confirmed transmission report
does not exist, then notice will be deemed given when the notice is actually
received by the person to whom it is sent. If delivered by overnight courier,
notice shall be deemed given when it has been signed for. If delivered by hand,
notice hall be deemed given when received.

10. SERVICES FOR OTHERS

As consultant will acquire or have access to information, which is of a highly
confidential and secret nature, consultant shall not perform any services for
any other person or firm on a specific topic which relates (i) to any area of
service rendered under this Agreement or (ii) to the confidential information
without Client's prior written approval.

11. TERMINATION

11.1 BREACH

If either party hereto breaches any of the terms or conditions of this
Agreement, the other party may terminate this Agreement immediately upon written
notice to the breaching party. Upon such termination, consultant will submit an
invoice to Client for all services satisfactorily performed, inEmployer's sole
determination, and reimbursable expenses incurred and paid by Consultant up to
the date of termination. If the termination is due to Consultant's breach of
this agreement, an adjustment will be made in payment depending on the nature of
the breach.

11.2 WITHOUT CAUSE

Either party may terminate this agreement without cause at any time upon 30 days
written notice. Upon receipt of such notice, consultant will discontinue work
and will submit an invoice to Client for all services satisfactorily performed,
in Client's or independent third party's determination, and reimbursable
expenses incurred and paid by consultant up to the date of receipt of notice of
termination.

12. SURVIVAL

The provisions of Sections 7, 8, and 11 shall survive expiration or termination
of this Agreement.

13. APPLICABLE LAW/PLACE OF JURISDICTION

This Agreement, all services performed under this Agreement and all disputes
between the parties arising out of or in connection with this Agreement are
solely governed by Florida law with the exception of the Law on the
International Sale of Goods or where Uniform Commercial Code (UCC) is
applicable.

                                       5

                                 GENBIOMICS, LLC
                     Investments for Pharmaceutical Research
________________________________________________________________________________

Place of exclusive jurisdiction is Tampa, Florida or unless otherwise agreed to
by mutual consent by both parties.

14. WARRANTY

Consultant warrants that its services hereunder will be of a professional
quality confirming the generally accepted industry standards and practices.

IN WITNESS WHEREOF, the parties hereto have executed this agreement

The day and year first above written.

                               __________________________________
        DNAPrint Genomics, Inc., Client

                               __________________________________
        GenBiomics, LLC, Consultant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]